TAVO-PLUS-CXCL9

N/A

Report date: 2025/05/14 14:16:45

Base Information

Drug NameTAVO-PLUS-CXCL9
Drug Alias NameTAVO-PLUS-CXCL9
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionInterleukin-12 stimulantsC-X-C motif chemokine 9 modulators
TargetsInterleukin-12C-X-C motif chemokine 9
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOncosec Medical
China Registration ClassN/A

Develop Information

Active CompaniesOncosec Medical
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A